Biotech Values

[genisi]

CANF/CF101 better potential market uptake in psoriasis than in RA

Can you elaborate on your reasons? Psoriasis has become almost as competitive a marketplace as RA.

I think that in psoriasis, both patients and docs are going to be more willing to use an oral agent with reasonable efficacy and very good safety profile considering the alternative, the nature of the disease, and that most patients are mild, and dermatologists do not prescribe biologics as much as rheumatologists.